2023 World Conference on Lung Cancer (Posters)-P1.28. Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy?

P1.28. Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy? - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to determine whether age is a barrier to receiving radical chemoradiotherapy or immunotherapy for stage III non-small cell lung cancer (NSCLC). The study included 265 patients treated for lung cancer at a major cancer center between January 2012 and June 2022. The patients had biopsy-proven NSCLC and were treated with curative-intent chemoradiotherapy or immunotherapy. The median follow-up period was 5.4 years.<br /><br />The results showed that age did not significantly affect overall survival. The univariable Cox regression analysis showed that age at diagnosis did not have a significant impact on survival, with a hazard ratio of 1.07 (95% CI: 0.93-1.23; p=0.347). The analysis also showed that age group (80 years or older) and age group (70 years or older) did not have a significant impact on survival. Additionally, age quartile groups (27.9-59.6 years, 59.6-66.4 years, 66.4-72.6 years, 72.6-88.3 years) did not have a significant impact on survival.<br /><br />Based on these findings, the study concludes that age alone is not a limitation to receiving radical chemoradiotherapy or immunotherapy for stage III NSCLC. The treatment can be offered to well-selected older patients. The study also highlights the importance of excellent supportive care availability at a major cancer center, which contributes to good outcomes for these patients.<br /><br />In summary, this study suggests that older patients with stage III NSCLC should not be excluded from receiving concurrent chemoradiotherapy or immunotherapy based solely on their age. Treatment decisions should be based on individual patient characteristics and overall health.

Asset Subtitle

Neil Wallace

Meta Tag

Speaker Neil Wallace

Topic Local-Regional NSCLC

Keywords

age

barrier

receiving

radical

chemoradiotherapy

immunotherapy

stage III

non-small cell lung cancer

NSCLC

overall survival